CliffBio
small molecule

BAXDELA

DELAFLOXACIN MEGLUMINE

Loss of exclusivityJune 2034latest FDA-listed patent expiry
CompanyMELINTA SUBSIDIARY CORP

Drug detail

Brand nameBAXDELA
Active ingredientDELAFLOXACIN MEGLUMINE
StrengthEQ 300MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2017
Marketing statusRX

Listed patents

PatentExpiresType
12036219June 2034use U-3967
12558349March 2034use U-3967
9493582February 2033product
12138257May 2032product
7728143June 2031substance
RE46617December 2029substance
8871938September 2029substance
7635773March 2029product
8410077March 2029product
9750822March 2029product
9200088March 2029product
8252813October 2026product
8273892August 2026substance

Regulatory exclusivity

CodeExpires
GAINJune 2027
NCEJune 2022

More from MELINTA SUBSIDIARY CORP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BAXDELA patent cliff — loss of exclusivity June 2034 | CliffBio